On August 1, 2025, the United States Pharmacopeia (USP) released Chapters <73> and <1071>, simplifying the adoption of ATP-bioluminescence-based Rapid Microbiological Methods (RMMs) like Celsis® for faster microbial testing. Rapid method regulatory approval has never been easier for pharmaceutical manufacturers. Read More >
In today’s world, quality and compliance are non-negotiable, and yesterday’s standards are no longer sufficient to meet the demands of a constantly evolving landscape. The field of quality control microbiology is undergoing a disruptive revolution to safeguard patient safety, evolving beyond traditional methods to optimize resources, minimize human error, enable sustainable alternatives, and maintain consistent quality standards. Every test, every result, and every data point define the success of life-changing therapies. That’s why we’re leading a new paradigm, one that redefines efficiency, sustainability, and innovation. Let’s rethink the future of microbial quality control, where modern, automated, data-centric, and scalable solutions are the norm, empowering you to stay ahead in a dynamic regulatory and operational landscape. Together, we are not just preparing for the future. We’re rethinking it. Because every moment matters.
This post is related to:
Stay informed on pharmacy supply chain news, market trends, and product releases by subscribing to RXinsider’s emails, newsletters, and publications. If building awareness with pharmacy management is part of your marketing strategy, consider advertising with RXinsider.
